Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 3 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 9Tumor-Agnostic 6Gynecologic 4Other solid neoplasm 3Genitourinary 2Other hematologic neoplasm 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 3Uterine Cervical Neoplasms 1Peritoneal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × nintedanib × Gynecologic × Clear all
NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Boehringer Ingelheim

Phase 1 Completed
19 enrolled 21 charts
Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

NCT01485874 2022-02-15

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Hoosier Cancer Research Network

Phase 1 Terminated
11 enrolled
Gynecologic

Ovarian Neoplasms

NCT02835833 2018-07-10

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1 Completed
21 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms

NCT01329549 2014-11-27

Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)

Boehringer Ingelheim

Phase 1 Terminated
2 enrolled 5 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡